Tempus AI (TEM) is Amongst AI stocks Under $30 That Carry High Short Interest

In early June, Tempus AI Inc. (NASDAQ: TEM) announced that its next-generation whole-genome sequencing assay, **xH**, is moving toward clinical availability. Designed to identify cancer-related genomic alterations in bone marrow and peripheral blood samples, the test aims to enhance the diagnosis and management of hematologic malignancies.

The xH assay supports the detection and analysis of several blood cancers and related disorders, including myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and MDS/MPN overlap syndromes. Beyond clinical diagnostics, it also serves as a valuable tool for biomarker identification, disease research, and the development of targeted therapies.

Analytical validation of the assay was conducted using 235 samples comprising cell lines, bone marrow, and whole blood specimens. The results demonstrated strong analytical performance, achieving a positive percent agreement (PPA) of 92.86% for structural variants (SVs), 93.43% for copy number alterations (CNAs), and 97.29% for single nucleotide variants (SNVs) and insertions/deletions (Indels), highlighting the test's reliability and accuracy.

According to CEO Tom Schonherr, the clinical launch of xH represents the realization of the company's vision to establish a standardized whole-genome sequencing platform capable of advancing the future of hematologic oncology. He emphasized that the technology has the potential to improve precision medicine by delivering more comprehensive genomic insights for both clinicians and researchers.

Tempus AI is a healthcare technology company that combines artificial intelligence with genomic data to support precision medicine. Its portfolio includes AI-powered platforms such as Tempus Platform, Next, Algos, Lens, and Hub, alongside diagnostic services for solid tumors and blood cancers, inherited genetic testing, and clinical trial matching solutions.

The launch of xH further strengthens Tempus AI's precision oncology ecosystem by expanding its whole-genome sequencing capabilities and enriching the high-quality genomic data that powers its AI-driven healthcare solutions.

Voice Of Osiz

At Osiz, we see Tempus AI's xH clinical launch as another strong indicator of how AI-powered genomics is reshaping precision healthcare. Advanced whole-genome sequencing, combined with intelligent data analytics, enables faster biomarker discovery, more accurate diagnoses, and personalized treatment strategies. As healthcare organizations increasingly adopt AI-driven genomic platforms, the demand for scalable, secure, and data-centric solutions will continue to rise. This evolution reinforces the importance of integrating AI with genomics to accelerate clinical decision-making and medical research. We believe innovations like xH highlight the growing role of AI in transforming complex healthcare workflows into data-driven, patient-centric outcomes. At Osiz, we empower healthcare innovators with advanced AI development solutions that unlock the full potential of next-generation precision medicine.

Source: Yahoo Finance